Shanghai Clinical Cohort - Esophageal Cancer

April 13, 2026 updated by: Zhigang Li, Shanghai Chest Hospital

Shanghai Clinical Cohort - Esophageal Cancer Cohort

A prospective cohort of patients who received esophagectomy for esophageal cancer in participating centers.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

A prospective cohort of patients who received esophagectomy for esophageal cancer in participating centers.

Study Type

Observational

Enrollment (Actual)

2116

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
      • Shanghai, China, 20030
        • Shanghai Chest Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients received esophagectomy for esophageal cancer.

Description

Inclusion Criteria:

  • Received esophagectomy in these centers for esophageal cancer.

Exclusion Criteria:

  • No esophagectomy.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Overal survival
Time Frame: From the date of enrollment until the date of death or loss of follow-up, assessed up to 10 years. Follow-up is scheduled every 3 months in the first 2 years. Every 6 months from the 2nd to the 5th year. Then once a year. Until death or loss of follow.
From the date of enrollment until the date of death or loss of follow-up, assessed up to 10 years. Follow-up is scheduled every 3 months in the first 2 years. Every 6 months from the 2nd to the 5th year. Then once a year. Until death or loss of follow.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Shanghai Chest Hospital

Collaborators

Shanghai Zhongshan Hospital
Shanghai Cancer Hospital, China
Changhai hospital of Navy Medical University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2025

Primary Completion (Actual)

March 31, 2026

Study Completion (Actual)

March 31, 2026

Study Registration Dates

First Submitted

November 17, 2025

First Submitted That Met QC Criteria

December 30, 2025

First Posted (Actual)

December 31, 2025

Study Record Updates

Last Update Posted (Actual)

April 15, 2026

Last Update Submitted That Met QC Criteria

April 13, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IS25163

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Esophageal Cancer

Clinical Trials on esophagectomy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovakia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe